CinCor Pharma, Inc. Report issue

For profit Phase 1 Phase 2
Founded: Cincinnati OH United States (2018)
Status: Acquired by AstraZeneca (2023)

Organization Overview

First Clinical Trial
2020
NCT04519658
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CinCor Pharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

vasopressin (vasostrict) (6 trials)

Drugs in Phase 1 Trials (1)

metformin (glucophage) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2